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The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
pandemic poses extra challenges for the management and treat-
ment of cancer patients. Scarce evidence has been published in the 
last months, and there is still no consensus on how to ensure the 
standard of care for these patients avoiding the risk of infection.1,2 
Therefore, in Lombardy (Italy) every institute, including IRCCS 
Maugeri of Pavia, is adopting internal procedures to reorganize the 
health care management.
In Italy, the first outbreak of this pandemic occurred at the end 
of February in a small city, which is about 45 km far from our center. 
Notably, SARS-CoV-2 caused more than 71 300 infections and about 
13 200 deaths in the region.3
Due to the virus’ high prevalence in Lombardy, several hospitals 
have reorganized themselves as COVID-19 center and elective sur-
gery has been interrupted. Thus, some patients affected by cancer 
could no longer be admitted to hospital and properly treated.
On one hand, cancer patients are at higher risk of COVID-19 in-
fection and more likely have higher morbidity and mortality than the 
general population.4,5 On the other hand, early diagnosis and treat-
ment of cancer patients should not be postponed nor compromised 
during a pandemic. Need for any interventional procedure must be 
balanced against increased risk of infection and should be evaluated 
on a case-by-case basis to address urgency of procedures.2
Lombardy health care system has suggested guidelines to man-
age COVID-19–free breast cancer patients needing hospitalization, 
and a color code was applied to each patient as following: red code 
(high priority, within 4 weeks), yellow code (medium priority, within 
8 weeks), and green code (low priority, >8 weeks).
The Breast Unit (BU) of IRCCS Maugeri is an EUSOMA-accredited 
tertiary referral center which performs more than 1100 breast sur-
gical procedures every year, including 500 procedures for primary 
breast cancer. At the beginning of the pandemic, breast cancer pa-
tients’ therapeutic and diagnostic paths had to be modified in order 
to guarantee early treatment to the most critical patients with non-
deferrable medical conditions.
We decided to delay the treatment of benign disease or low-
grade malignancies and to postpone reconstructive surgery.
Every patient hospitalized for scheduled surgery underwent 
blood examinations (to rule out leukocytosis or lymphopenia) and 
a chest X-ray. Moreover, patients filled out specific questionnaires 
to self-certify the absence of symptoms in the previous 14 days or 
contacts with COVID-19–infected subjects. From March 21, 2020, 
specific pathways of access to COVID-19 areas were created, since 
our institute was partially converted as a COVID-19 referral center.
In order to specifically protect breast cancer patients, breast 
elective surgery was interrupted from April 6 to April 18, 2020. 
Then, breast surgical activities restarted and we improved our safety 
measures as follows:
• All the medical and nursing staff and patients performed screen-
ing for SARS-CoV-2 infection, provided through nasopharyngeal 
swab.
• The patients stayed in single rooms to minimize contacts with 
other patients. The admission of relatives to the ward was not 
allowed.
• No prehospitalization was performed to limit hospital access; all 
preoperative routine assessment was performed the day before 
surgery during hospitalization.
• Patients who needed localization of sentinel lymph node were 
submitted to indocyanine green (ICG) breast subdermic injection 
directly in the operating room. This avoided displacement through 
different departments, as before the COVID-19 era we were used 
to perform axillary lymphoscintigraphy at the Nuclear Medicine 
Department.
• Fresh tissue requiring an intraoperative consultation (or frozen 
section) could potentially cause infection. For that reason, the 
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pathology service used a cryostat microtome that prevents the 
dispersion of any aerosol produced during the procedure as well 
as all necessary personal protective equipment (PPE).
• We continued to guarantee our multidisciplinary meetings in a re-
stricted form: one surgeon, one oncologist, and one radiotherapist, 
by respecting adequate social distance and by wearing a mask. 
Other staff members could contribute through a conference call.
• Genetics consults were performed by a video call between pa-
tients and physicians.
• Daily ward activity was planned in order to have the least number 
of team workers present to minimize the risk of infection.
• The Biobank for Research “Bruno Boerci” at the IRCCS Maugeri 
did not stop collecting biological samples.
From March 21 to April 24, 2020, we treated a total of 63 pa-
tients (vs 93 in the same timeframe in 2019). As compared to the last 
year, a difference was found in benign breast lesions (31% in 2019% 
vs 4% in 2020, P < .00001, Table 1).
Only one breast cancer patient, aged more than 75, developed 
respiratory symptoms and resulted positive for COVID-19 during 
the hospitalization. She was immediately transferred to a dedicated 
COVID-19 ward, and thanks to our safety measures none of our staff 
or other patient became infected.
We did not observe delays in histological diagnosis nor changes 
in radiotherapy or chemotherapy plans.
We had a significant reduction in diagnostic activity (about 70%) and 
a significant reduction in the number and duration of operating sessions.
In conclusion, the reorganization of our BU and ward ensured 
adequate and safety treatment for breast cancer patients.
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TA B L E  1   Clinical and pathological characteristics of breast 
cancer patients referred to our BU
Breast cancer 
lesions 
operated in 
March-April 
2019 (n = 93)
Breast cancer 
lesions during 
COVID-19 
pandemic 
(n = 63) P-value
Patients’ age at 
diagnosis (years)
58 (±15.5) 61 (±13.8) .16
Neo-adjuvant treatment
No 83 (89%) 58 (92%) .56
Yes 10 (11%) 5 (8%)
Surgerya 
Lumpectomy 78 (84%) 47 (69%) .03
Mastectomy 15 (16%) 21 (31%)
SLNBa 
No 40 (43%) 26 (38%) .54
Yes 53 (57%) 42 (62%)
Postoperative stay 
(days)
2.5 (±1.6) 2.8 (±1.7) .26
Complications
Yes 2 (2%) 3 (5%) .36
No 91 (98%) 60 (95%)
Histologya 
Benign 29 (31%) 3 (4%) <.00001
DCIS 6 (6%) 3 (4%)
CDI 49 (53%) 42 (62%)
CLI 9 (10%) 20 (30%)
pT stagea 
pTIS/Benign 
lesions
35 (38%) 6 (9%) .0003
pT1 46 (49%) 40 (59%)
pT2 12 (13%) 15 (22%)
pT3 0 (0%) 6 (9%)
pT4 0 (0%) 1 (1%)
pN stagea 
pN0/pNx 74 (80%) 54 (79%) .98
pN1-2-3 19 (20%) 14 (21%)
Indication for adjuvant CT
No 74 (80%) 24 (38%) <.00001
Yes 19 (20%) 39 (62%)
aValues refer to total number of lesions n = 68. Five patients have 
bilateral breast cancer. 
